X0704 D LIVE 0001430306 Tonix Pharmaceuticals Holding Corp. 509 MADISON AVE. - SUITE 306 NEW YORK NY NEW YORK 10022 212-980-9155 NEVADA TAMANDARE EXPLORATIONS INC. Corporation true 2008 Seth Lederman 509 MADISON AVE., SUITE 306 New York NY NEW YORK 10022 Executive Officer Director David Moss 509 MADISON AVE., SUITE 306 NEW YORK NY NEW YORK 10022 Director Benjamin Selzer 509 MADISON AVE., SUITE 306 NEW YORK NY NEW YORK 10022 Executive Officer Rhonda Rosen 509 MADISON AVE., SUITE 306 NEW YORK NY NEW YORK 10022 Executive Officer Susan Kerridge 509 MADISON AVE., SUITE 306 NEW YORK NY NEW YORK 10022 Executive Officer Pharmaceuticals Decline to Disclose 06 false 2011-10-07 false true true true true true Sold convertible debentures. Upon conversion or repayment, holder is entitled to receive additional consideration of a warrant or additional shares of common stock. true Private Placement was conducted in conjunction with a Reverse Merger 10000 WFG Investments, Inc 22704 None None 2711 N. HASKELL AVE., SUITE 2900 DALLAS TX TEXAS 75204 CA CALIFORNIA NY NEW YORK PA PENNSYLVANIA TX TEXAS false 3000000 1625000 1375000 In addition, the Company is allowing holders of $500,000 of principle face amount of old notes to exchange the old notes for secured debentures false 16 240000 true 0 A maximum of $240,000 of sales commissions may be due and payable, of which, $40,000 has been paid to date 0 false Tonix Pharmaceuticals Holding Corp. /s/ Seth Lederman Seth Lederman President and Chief Executive Officer 2011-10-20